Список проголосовавших за комментарий " On The Wires<ul><li>Asterias Biotherapeutics, Inc. (<strong>AST</strong>) announced that the company will host a conference call on Tuesday, January 24, 2017 to discuss new data evaluating the efficacy results six months after implantation of 10 million AST-OPC1 cells in patients with complete cervical spinal cord injuries in the ongoing SCiStar study. </li><li>Peoples Bancorp Inc. (<strong>PEBO</strong>) announced that Thomas J. Wolf has resigned from its Board of Directors («Board») and the Board of Directors of its banking subsidiary, Peoples Bank, effective January 14, 2017. Mr. Wolf had served on the Board since 2004. He was a member of the Board's Audit, Risk and Executive Committees, and he served as Chairman of the Audit Committee from August of 2010 until June of 2016.</li><li>Paratek Pharmaceuticals (<strong>PRTK</strong>) announced that it has completed enrollment in the pivotal Phase 3 clinical study evaluating omadacycline for the treatment of Community Acquired Bacterial Pneumonia. This study, which is designed to assess the efficacy and safety of intravenous to once-daily oral omadacycline compared with moxifloxacin in subjects with CABP, enrolled its first patient in November 2015. The co expects to report top-line data from this study in the second quarter of 2017.</li></ul>"